PR Newswire08.10.17
Nextremity Solutions Inc., a strategic commercialization organization with a focus on the musculoskeletal space, has announced the limited release of its newest product, the PiroVue Gastrocnemius Recession System for the treatment of equinus deformities in patients.
According to a report in the 2015 Podiatry Management by Patrick A Deheer, D.P.M., entitled, “The Non-Surgical Treatment of Equinus”, equinus deformity has been associated with over 96 percent of biomechanically related foot and ankle pathologies. An equinus deformity is a condition that limits the bending motion of the ankle joint. A patient with this deformity lacks the flexibility to raise their foot up and has a tendency to apply too much pressure to the bones in the forefoot. Equinus deformity can contribute to foot problems such as plantar fasciitis, metatarsalgia, arthritis of the midfoot, bunions, hammertoes, and more.”
PiroVue is a disposable, single use, sterile packed instrument kit for gastrocnemius recession. It consists of an integrated cutting guide and retractor with a controlled recession knife.
“We’re excited about the launch of PiroVue, a solution born from the frustration and ingenuity of our surgeons. Our surgeons are passionate about this gastrocnemius recession procedure and the resulting benefits they’ve seen in their patients. This disposable, cost-effective solution for gastrocnemius and soleus recession will potentially result in less muscle atrophy and weakness, as well as early weight bearing, relatively shorter periods of cast immobilization, while reducing risks to the sural nerve. Our hope is that PiroVue will allow for continued adoption and growth of this surgical procedure.” commented Ryan S. Schlotterback, chief commercialization officer for Nextremity Solutions.
The patent-pending PiroVue Gastrocnemius Recession System will utilize a limited launch with key surgeons prior to a full commercial launch in the first quarter of 2018.
Nextremity President and CEO Rod K. Mayer added, “Our goal as a part of our i3TMStrategic Solutions initiative is to continue to workwith surgeons to address their unmet needs in their respective surgical specialties. Our passion for creating innovative product solutions is to positively and significantly impact the lives of patients. If through the PiroVue Gastrocnemius Recession System patients can potentially get them back on their feet sooner with less issues, then we have succeeded.”
Nextremity Solutions is a privately held strategic commercialization organization with a focus on the musculoskeletal space, offering solutions and Revenue Ready products for various musculoskeletal applications and for the benefit of industry partners. The Warsaw, Ind.-based company’s procedure-ready, sterile implant systems include precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.
According to a report in the 2015 Podiatry Management by Patrick A Deheer, D.P.M., entitled, “The Non-Surgical Treatment of Equinus”, equinus deformity has been associated with over 96 percent of biomechanically related foot and ankle pathologies. An equinus deformity is a condition that limits the bending motion of the ankle joint. A patient with this deformity lacks the flexibility to raise their foot up and has a tendency to apply too much pressure to the bones in the forefoot. Equinus deformity can contribute to foot problems such as plantar fasciitis, metatarsalgia, arthritis of the midfoot, bunions, hammertoes, and more.”
PiroVue is a disposable, single use, sterile packed instrument kit for gastrocnemius recession. It consists of an integrated cutting guide and retractor with a controlled recession knife.
“We’re excited about the launch of PiroVue, a solution born from the frustration and ingenuity of our surgeons. Our surgeons are passionate about this gastrocnemius recession procedure and the resulting benefits they’ve seen in their patients. This disposable, cost-effective solution for gastrocnemius and soleus recession will potentially result in less muscle atrophy and weakness, as well as early weight bearing, relatively shorter periods of cast immobilization, while reducing risks to the sural nerve. Our hope is that PiroVue will allow for continued adoption and growth of this surgical procedure.” commented Ryan S. Schlotterback, chief commercialization officer for Nextremity Solutions.
The patent-pending PiroVue Gastrocnemius Recession System will utilize a limited launch with key surgeons prior to a full commercial launch in the first quarter of 2018.
Nextremity President and CEO Rod K. Mayer added, “Our goal as a part of our i3TMStrategic Solutions initiative is to continue to workwith surgeons to address their unmet needs in their respective surgical specialties. Our passion for creating innovative product solutions is to positively and significantly impact the lives of patients. If through the PiroVue Gastrocnemius Recession System patients can potentially get them back on their feet sooner with less issues, then we have succeeded.”
Nextremity Solutions is a privately held strategic commercialization organization with a focus on the musculoskeletal space, offering solutions and Revenue Ready products for various musculoskeletal applications and for the benefit of industry partners. The Warsaw, Ind.-based company’s procedure-ready, sterile implant systems include precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.